Summary - A new market study, titled “Global Diabetes Therapeutics Market - 2018 - 2025” has been featured on
The global diabetes Therapeutics market is estimated to be USD XX million in 2017 and the market is estimated to grow at a CAGR of XX% in the forecasted period to reach a market value of USD XX million by 2025.
Growing focus on regenerative therapies, presence of strong product pipeline portfolio, companies focus on oral insulin therapies, and growing technological advancements across the world which are helping in R&D are some of the key trends in the global diabetes therapeutics market.
Consumer’s preference on self-medication for the treatment of diabetes, growing demand for biologics, presence of high unmet needs, and large scope for Dimethyl disulphide (DMD’s) are some of the key factors driving the growth of the diabetes therapeutics market.
Growing complexity in storage and distribution of the insulin, highly unpredictable nature of drugs in the outcome on humans, raising concerns in the scientific communities and gap in the national level diabetes management plans are some of the key challenges for the growth of the diabetes therapeutics market.
Segmentation by Disease Type
The diabetes therapeutics market by disease type has been segmented into type 1 diabetes, type 2 diabetes, and Gestational diabetes. Type 2 diabetes is one of the most prevalent types of diabetes across the world. The majority of the population suffering with diabetes is the older population, though it is estimated the market is growing at a higher rate in younger population. By marketed products, Actos, Januvia, Lantus, and Lantus Solostar have the highest revenue share in United States. The gestational diabetes market is growing at a highest growth rate in the forecasted period.
Segmentation by Geography
North America dominates the global diabetes therapeutics market share in 2017 and the region is estimated to dominate the global market by the end of the forecasted period 2025. Growing prevalence of diabetes in United States and potential opportunities for the development of the high unmet needs, growing demand for safer and efficient drug are the major factors for the market to dominate by the end of forecasted period. The prevalence of type II diabetes in Europe is increasing due to changing lifestyle and changing food consumption preferences.
The global diabetes therapeutics market is a consolidated market with 90% of the market being dominated by top 10 companies in the industry. Novo Nordisk, Sanofi, Eli Lilly and Merck are some of the major companies in the diabetes therapeutics industry with these four companies occupying more than 70% of the market share in 2017. Merck is estimated to significantly loose it’s more than half of market share by the end of the forecasted period 2025 with Boehringer Ingelheim gaining the large market share. Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Sanofi with have the largest market share in 2025 with these four companies occupying 72.6% market share.
Scope of the Report
Segmentation by Marketed Drugs
Humalog (Eli Lilly)
Victoza (Novo Nordisk)
Trulicity (Eli Lilly)
Levemir (Novo Nordisk)
Trajenta (Boehringer Ingelheim)
Novolog (Novo Nordisk)
Segmentation by Diseases
Type 1 diabetes
Type 2 diabetes
Segmentation by Drug Class
The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Why Purchase the Report?
- Visualize the composition of the global diabetes therapeutics market with clear distinction between each design type and usage type.
- Identify commercial opportunities in the global diabetes therapeutics market analysing trends and co-development deals.
- Excel data sheet with thousands of data points of the global diabetes therapeutics market.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key products of all major market players
- Equipment Suppliers/ Buyers
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
About Us:Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +162-826-80070 (US)
Ph: +44 203 500 2763 (UK)